Test Price
2,800 AED✅ Home Collection Available
CLCNKB Gene Bartter Syndrome Type 3 Genetic Test in UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary
• 99.9% Diagnostic Accuracy – ISO‑accredited next‑generation sequencing with 100% coverage of all coding exons.
• VIP Mobile Phlebotomy & Home Collection – Hospital‑grade, temperature‑controlled cold‑chain collection available daily from 8 AM to 11 PM.
• Post‑Test Guidance Call – Complimentary clinical guidance call with a genetics counsellor to interpret results.
• Direct Insurance Verification – Verify coverage via WhatsApp on +971 54 548 8731.
Test Overview & Methodology
This next‑generation sequencing (NGS) test fully interrogates the CLCNKB gene to diagnose Bartter syndrome type 3, an autosomal recessive renal salt‑wasting tubulopathy. The assay achieves ≥99.9% detection rate for single‑nucleotide variants, small indels, and copy‑number changes using the Illumina platform. Pre‑test genetic counselling is required to draw a pedigree and obtain informed consent.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Detection Rate | ≥99.9% for single‑nucleotide variants, small indels, and copy‑number changes | ~90–95% per amplicon; full gene analysis requires multiple reactions |
| Turnaround Time | 3‑4 Weeks | 6‑8 Weeks for complete gene coverage |
| Cost‑Efficiency | One comprehensive assay at 2800 AED | Cumulative cost of sequential exon‑by‑exon testing often exceeds 5000 AED |
Physician Insight & Safety Protocols
“A comprehensive genetic analysis of the CLCNKB gene is essential for confirming Bartter syndrome type 3 and guiding appropriate management. I encourage patients to discuss the implications of their results with their healthcare provider.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Precautions
- Do not adjust or discontinue any prescribed medications without consulting your physician.
- Pre‑test genetic counselling is required to discuss family history and obtain informed consent as per UAE regulations.
- Inform your doctor of any recent blood transfusions or bone marrow transplants, as these may affect test accuracy.
Exclusion Criteria & Emergency Signs
Exclusion Criteria
- Recent blood transfusion or bone marrow transplant (within 2 weeks) – risk of donor DNA contamination.
- Acute critical illness without physician clearance – electrolyte imbalances may mimic Bartter crisis.
- Inability or unwillingness to provide informed consent after genetic counselling.
Emergency Red Flags
- Severe muscle cramps, tetany, or uncontrollable spasms.
- Palpitations, irregular heartbeats, or sudden confusion.
- Profound weakness or paralysis – seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What does this test detect?
This NGS test comprehensively analyzes the CLCNKB gene for pathogenic variants causing Bartter syndrome type 3, a salt‑wasting renal tubulopathy that leads to electrolyte imbalances.
2. How should I prepare for sample collection?
No fasting or medication changes are required unless advised by your physician. A simple blood draw or FTA card collection is sufficient.
3. What is the clinical utility of the result?
A positive result confirms diagnosis, guides salt and potassium supplementation, and triggers family screening. A negative result reduces the need for invasive investigations.
UAE Regulatory & Data Privacy Adherence
We strictly adhere to the UAE's data protection and health information laws:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree‑Law No. 4 of 2016 on Medical Liability
All genetic data is processed with the highest confidentiality and security standards. DNA Labs UAE is licensed under DHA Facility License 1143.
Clinical & Logistical Metadata
| Test Name | CLCNKB Gene Bartter Syndrome Type 3 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3‑4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted DNA, or FTA card |
| Methodology Used | Next‑Generation Sequencing (Illumina platform) |
| ICD‑10‑CM Code | E26.81 |
| LOINC Code | 55189-6 |
| DHA Facility License & Address | DNA Labs UAE – DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians